The company’s operating loss increased by $11.2 million compared to 2012. The loss corresponds with the company’s decision to discontinue the PurGen Osteoprogenitor Cell Allograft from its product portfolio after a significant investment in clinical trials.
Gross profit dropped 18 percent to $24.2 million, though its revenue increased 7 percent to $50 million.
More Articles on Supply Chain:
DMP Spine Biologics to Distribute Bacterin Bone Graft Products in Europe
LDR Holdings Reports $8M Q3 Net Loss
MAKO Surgical Suffers $21.3M Net Loss in Q3, Decreased RIO Sales
